Baxter International Inc (BAX)

How it makes money

Baxter sells products through multiple channels: direct relationships with hospital systems and clinics, group purchasing organizations (GPOs), integrated delivery networks (IDNs), medical distributors, and direct-to-patient home infusion services. Approximately 55% of revenue comes from the United States, with 45% from international markets across more than 100 countries.

Revenue by segment

Baxter benefits from scale through operations in over 100 countries and breadth of product offerings that create switching costs for hospitals. The company holds leading positions in IV solutions and connected care technologies. However, the moat is narrow because pricing power is significantly constrained by consolidated buyer power of group purchasing organizations and integrated delivery networks, creating leverage for customers that offsets Baxter's scale advantages. Intense competition from specialized competitors and generic alternatives limits pricing flexibility.

Demand for Baxter's products is driven by demographic and clinical trends that provide underlying growth resilience: the global population aged 60 and older is growing from 1.1 billion to 1.4 billion by 2030, driving higher incidence of chronic diseases and need for continuous therapies. The global IV therapy market is projected to grow approximately 5.5% annually through 2029, driven by these structural factors rather than purely cyclical economic conditions. However, healthcare spending can be affected by economic downturns and hospital budget cycles, creating moderate cyclicality.

Key risks

• Pricing Pressure and Cost Recovery Limitations — Group purchasing organizations, integrated delivery networks, and government procurement authorities exert ongoing pricing pressure that limits Baxter's ability to raise prices. In 2022-2024, the company was unable to fully offset raw material and component cost increases through customer pricing adjustments, resulting in margin compression.
• Supply Chain Vulnerabilities and Cost Inflation — Global supply chain disruptions continue to impact production, with shortages of raw materials and critical components, production delays, and increased costs. The company faces single-source supplier dependencies for certain materials, and qualifying alternative suppliers creates operational risks and delays.
• Generic Competition and Patent Exposure — The pharmaceutical segment faces exposure to generic competition and patent litigation. Generic injectable products and competitive alternatives can erode pricing and market share in key therapeutic areas, particularly as patents expire on marketed products.
• International Operations and Currency Risk — With 45% of revenue from international markets, Baxter faces exposure to foreign currency fluctuations, regulatory changes, geopolitical events, varying reimbursement policies, and differing market dynamics across regions. Currency headwinds can reduce reported revenues and operating results.

Baxter has significant customer concentration risk concentrated through group purchasing organizations and integrated delivery networks rather than individual customer concentration. The company has purchasing agreements with several major U.S. GPOs that collectively represent a substantial portion of U.S. revenue. While no single customer represents more than a small percentage of total revenue, the consolidated buying power of major hospital systems and GPOs creates effective concentration risk and pricing leverage concentrated among a limited number of very large buyers. The United States represents 55% of consolidated revenue.